← Back to Search

Procedure

TLD for COPD (AIRFLOW-3 Trial)

N/A
Waitlist Available
Led By Frank Sciurba, MD
Research Sponsored by Nuvaira, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subject ≥40 years of age at the time of consent;
Women of child bearing potential must not be pregnant, evidenced by a negative pregnancy test (blood or urine) pre-treatment, or lactating and agree not to become pregnant for the duration of the study;
Timeline
Screening 3 weeks
Treatment Varies
Follow Up randomization to 12 months, 3 to 12 months
Awards & highlights

AIRFLOW-3 Trial Summary

This trial is testing a new device to treat COPD. The device is safe and effective.

Who is the study for?
Adults over 40 with COPD who've had at least 2 moderate or 1 severe exacerbation in the past year, despite optimal medical care. They must not smoke, have a CAT score ≥10, FEV1 between 25-80% predicted, and agree to flu vaccinations. Excluded are those with certain other diseases or conditions that could affect study participation or those on high doses of steroids.Check my eligibility
What is being tested?
The trial is testing the Nuvaira Lung Denervation System's safety and effectiveness for treating COPD compared to optimal medical care alone. It involves a procedure called Targeted Lung Denervation (TLD) which aims to reduce nerve signals that cause airway constriction.See study design
What are the potential side effects?
Potential side effects may include reactions related to bronchoscopy or general anesthesia such as sore throat, coughing, shortness of breath; complications from lung denervation like chest discomfort; and risks associated with medications used during the procedure.

AIRFLOW-3 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 40 years old or older.
Select...
I am not pregnant or breastfeeding and agree not to become pregnant during the study.
Select...
I am 40 years old or older.
Select...
I am not pregnant or breastfeeding and agree to avoid pregnancy during the study.
Select...
I have COPD with specific lung function test results.

AIRFLOW-3 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~randomization to 12 months, 3 to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and randomization to 12 months, 3 to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Moderate or severe COPD exacerbations
Secondary outcome measures
CAT responders
Change in FEV1
Change in FVC
+7 more
Other outcome measures
Adverse event rates
Changes in dyspnea
Changes in lung function
+3 more

AIRFLOW-3 Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active TreatmentExperimental Treatment2 Interventions
Target Lung Denervation (TLD) with the Nuvaira Lung Denervation System (RF energy delivered) and optimal medical care for COPD.
Group II: Sham ControlPlacebo Group1 Intervention
Sham Targeted Lung Denervation (TLD) procedure with the Nuvaira Lung Denervation System (catheter placement and balloon deployment in all treatment locations, no RF energy delivered) and optimal medical care for COPD.

Find a Location

Who is running the clinical trial?

Nuvaira, Inc.Lead Sponsor
5 Previous Clinical Trials
167 Total Patients Enrolled
Frank Sciurba, MDPrincipal InvestigatorUniversity of Pittsburgh Medical Center
4 Previous Clinical Trials
2,307 Total Patients Enrolled
Dirk-Jan Slebos, MD, PhDPrincipal InvestigatorUniversity Medical Center Groningen
4 Previous Clinical Trials
98 Total Patients Enrolled

Media Library

Nuvaira Lung Denervation System (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT03639051 — N/A
Chronic Obstructive Pulmonary Disease Research Study Groups: Sham Control, Active Treatment
Chronic Obstructive Pulmonary Disease Clinical Trial 2023: Nuvaira Lung Denervation System Highlights & Side Effects. Trial Name: NCT03639051 — N/A
Nuvaira Lung Denervation System (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03639051 — N/A
Chronic Obstructive Pulmonary Disease Patient Testimony for trial: Trial Name: NCT03639051 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people are currently enrolled in this experiment?

"To satisfy the set parameters of this trial, 480 eligible patients must take part. These individuals will be sourced from two particular medical centres, namely University of Michigan in Ann Arbor and HonorHealth in Phoenix."

Answered by AI

Is the clinical trial available at a variety of locations within this city?

"This medical study is being conducted from the University of Michigan in Ann Arbor, HonorHealth in Phoenix, and Spectrum Health Medical Group in Grand Rapids. Additionally, 20 additional sites are also a part of this clinical trial."

Answered by AI

Are there opportunities for patients to enroll in this clinical trial currently?

"According to the records available on clinicaltrials.gov, this investigation has been open for recruitment since May 23rd 2019 and is up-to-date as of May 9th 2022."

Answered by AI

Who else is applying?

What state do they live in?
Florida
Texas
Other
North Carolina
How old are they?
18 - 65
What site did they apply to?
University of Alabama at Birmingham (UAB) Lung Health Center
Harbor UCLA
Houston Methodist Hospital
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
1
0
3+
2

Why did patients apply to this trial?

To find a better way to treat this disease and help others in the future. I am always hopeful to find something that will help my shortness of breath.
PatientReceived 1 prior treatment
Recently (last week) I had a flare up and thought if this can’t help me maybe I can help someone else.
PatientReceived 1 prior treatment
Recent research and studies
~29 spots leftby Sep 2024